Citations

Mayo Clinic

Showing 10 of 108522 citations.

The prevalence of substance use disorders in American physicians
Oreskovich, Michael R., Sotile, Wayne M., Satele, Daniel , Sloan, Jeff A. , Boone, Sonja, Shanafelt, Tait D. , Dyrbye, Liselotte N. , Tan, Litjen , West, Colin P.

The American Journal on Addictions | November 20, 2014 | Volume: No volume available | Issue: No issue available | Pages: n/a-n/a

10.1111/j.1521-0391.2014.12173.x Get It

α 2A adrenergic receptor promotes amyloidogenesis through disrupting APP-SorLA interaction
Peng, Yin, Che, Pulin , Gannon, Mary , Liu, Yin , Li, Ling , Bu, Guojun , Groen, Thomas van , Jiao, Kai , Wang, Qin , Chen, Yunjia , Peng, Yin, Bu, Guojun

Proceedings of the National Academy of Sciences | November 20, 2014 | Volume: 111 | Issue: 48 | Pages: 17296-17301

10.1073/pnas.1409513111 | PMID 25404298 Get It

Significance Endocytic sorting of amyloid precursor protein (APP) governed by the vacuolar protein sorting (Vps10) family of receptors plays a decisive role in controlling the outcome of APP proteolytic processing and the generation of amyloid β (Aβ) peptides, the key pathogenic factor of Alzheimer's disease (AD). This study provides the first evidence to our knowledge that a G protein-coupled receptor, namely, the α 2A adrenergic receptor, modulates APP endocytic sorting and promotes Aβ generation through disrupting APP interaction with a Vps10 family protein, sorting-related receptor with A repeat. Significantly, blockade of α 2A AR by a clinical antagonist reduces AD-related pathology and ameliorates cognitive deficits in an AD transgenic model, suggesting repurposing clinical α 2 AR antagonists as a new direction for AD treatment.
Dual Proinflammatory and Antiviral Properties of Pulmonary Eosinophils in Respiratory Syncytial Virus Vaccine-Enhanced Disease
Su, Yung-Chang, Townsend, Dijana , Herrero, Lara J. , Zaid, Ali , Rolph, Michael S., Gahan, Michelle E. , Nelson, Michelle , Rudd, Penny A. , Matthaei, Klaus I., Foster, Paul S. , Dent, Lindsay A. , Simson, Ljubov, Tripp, Ralph A. , Lee, James S. , Mahalingam, Suresh

Journal of Virology | November 20, 2014 | Volume: 89 | Issue: 3 | Pages: 1564-1578

10.1128/jvi.01536-14 | PMID 25410867 Get It

ABSTRACT Human respiratory syncytial virus (RSV) is a major cause of morbidity and severe lower respiratory tract disease in the elderly and very young, with some infants developing bronchiolitis, recurrent wheezing, and asthma following infection. Previous studies in humans and animal models have shown that vaccination with formalin-inactivated RSV (FI-RSV) leads to prominent airway eosinophilic inflammation following RSV challenge; however, the roles of pulmonary eosinophilia in the antiviral response and in disease pathogenesis are inadequately understood. In vivo studies in mice with eotaxin and/or interleukin 5 (IL-5) deficiency showed that FI-RSV vaccination did not lead to enhanced pulmonary disease, where following challenge there were reduced pulmonary eosinophilia, inflammation, Th2-type cytokine responses, and altered chemokine (TARC and CCL17) responses. In contrast to wild-type mice, RSV was recovered at high titers from the lungs of eotaxin- and/or IL-5-deficient mice. Adoptive transfer of eosinophils to FI-RSV-immunized eotaxin- and IL-5-deficient (double-deficient) mice challenged with RSV was associated with potent viral clearance that was mediated at least partly through nitric oxide. These studies show that pulmonary eosinophilia has dual outcomes: one linked to RSV-induced airway inflammation and pulmonary pathology and one with innate features that contribute to a reduction in the viral load. IMPORTANCE This study is critical to understanding the mechanisms attributable to RSV vaccine-enhanced disease. This study addresses the hypothesis that IL-5 and eotaxin are critical in pulmonary eosinophil response related to FI-RSV vaccine-enhanced disease. The findings suggest that in addition to mediating tissue pathology, eosinophils within a Th2 environment also have antiviral activity.
Prognostic Value of a Simplified Anatomically Based Nomenclature for Fetal Nuchal Lymphatic Anomalies
Longstreet, Beck, Balakrishnan, Karthik , Saltzman, Babette S., Dighe, Manjiri , Perkins, Jonathan A. , Balakrishnan, Karthik

Otolaryngology–Head and Neck Surgery | November 20, 2014 | Volume: 152 | Issue: 2 | Pages: 342-347

10.1177/0194599814559190 | PMID 25411310 Get It

ObjectiveTo propose an anatomic classification for fetal nuchal lymphatic anomalies that will be clinically useful and to evaluate the classification’s value in predicting chromosomal abnormalities, pregnancy outcomes, other associated fetal anomalies, and spontaneous resolution of these lesions.Study DesignRetrospective cohort study.SettingTertiary academic hospital and affiliated tertiary children’s hospital.Subjects and MethodsMother‐baby pairs diagnosed with fetal nuchal lymphatic anomalies in a prenatal ultrasound database. Anomalies were classified as nuchal thickening, dorsal lymphatic malformation, or ventral lymphatic malformation. Pregnancy outcomes, prevalence of chromosomal and anatomic abnormalities, and rates of spontaneous lesion resolution were determined for each group.ResultsThe study included 189 patients: 58 with nuchal thickening, 120 with dorsal lymphatic malformation, and 11 with ventral lymphatic malformation. In fetuses for whom chromosomal analysis was available, chromosomal abnormalities were strongly associated with dorsal lymphatic malformations (83%), less associated with nuchal thickening (29%), and not associated with ventral lymphatic malformations. Dorsal lymphatic malformation predicted high rates of elective (43%) and spontaneous (20%) termination of pregnancy and showed the strongest association with cardiac, renal, and skeletal anomalies. Nuchal thickening was more likely to resolve in utero than dorsal lymphatic malformations, while no ventral lymphatic malformation resolved spontaneously.ConclusionsFetal nuchal anomalies demonstrate significant and clinically important prognostic differences depending on their anatomic location. The simple classification system proposed here therefore provides useful information to clinicians involved in the pre‐ and postnatal management of children with these anomalies.
Incident Pneumonia and Mortality in Patients with Chronic Obstructive Pulmonary Disease. A Double Effect of Inhaled Corticosteroids?
Festić, Emir , Scanlon, Paul D.

American Journal of Respiratory and Critical Care Medicine | November 19, 2014 | Volume: 191 | Issue: 2 | Pages: 141-148

10.1164/rccm.201409-1654pp | PMID 25409118 Get It

Abstract Inhaled corticosteroids are commonly prescribed for patients with severe chronic obstructive pulmonary disease. Although their use improves quality of life and reduces exacerbations, it is associated with increased risk of pneumonia. Curiously, their use has not been associated with increased risk of pneumonia-related or overall mortality. We review pertinent literature to further explore the effects of inhaled corticosteroids on incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. The association of use of inhaled corticosteroids and incident pneumonia is substantial and has been present in the majority of the studies on the topic. This includes both randomized controlled trials and observational studies. However, all of the studies have substantial risk of bias. Most randomized trials are limited by lack of systematic ascertainment of pneumonia; they depended on adverse event reporting. Many observational studies included proper radiographic assessment of pneumonia, but they are limited by their retrospective, observational design. The unadjusted higher risk of pneumonia is associated with longer duration of use, more potent ICS compounds, and higher doses. That implies a dose–effect relationship. Unlike pneumonia, mortality is a precise outcome. Despite the robust association of inhaled corticosteroid use with increased risk of pneumonia, all studies find either no difference or a reduction in pulmonary-related and overall mortality associated with the use of inhaled corticosteroids. These observations suggest a double effect of inhaled corticosteroids (i.e., an adverse effect plus an unexplained mitigating effect).
A Time to Die
Odunukan, Olufunso W.

Journal of Palliative Medicine | November 19, 2014 | Volume: 17 | Issue: 12 | Pages: 1404-1405

10.1089/jpm.2014.0013 | PMID 25407301 Get It

Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment
Gertz, Morie A.

American Journal of Hematology | November 19, 2014 | Volume: 89 | Issue: 12 | Pages: 1132-1140

10.1002/ajh.23828 | PMID 25407896 Get It

Disease Overview: Immunoglobulin light chain amyloidosis is a clonal, nonproliferative plasma cell disorder in which fragments of immunoglobulin light chain are deposited in tissues. Clinical features depend on organs involved but can include restrictive cardiomyopathy, nephrotic syndrome, hepatic failure, peripheral/autonomic neuropathy, and atypical multiple myeloma.Diagnosis: Tissue biopsy stained with Congo red demonstrating amyloid deposits with apple‐green birefringence is required for diagnosis. Invasive organ biopsy is not required because amyloid deposits can be found in bone marrow biopsy or subcutaneous fat aspirate in 85% of patients. Verification that amyloid is composed of immunoglobulin light chains is mandatory.Prognosis: N‐terminal pro‐brain natriuretic peptide (NT‐proBNP), serum troponin T, and difference between involved and uninvolved immunoglobulin free light chain values are used to classify patients into four groups of similar size; median survivals are 94.1, 40.3, 14.0, and 5.8 months.Therapy: All patients with a systemic amyloid syndrome require therapy to prevent deposition of amyloid in other organs and prevent progressive organ failure of involved sites. Stem cell transplant (SCT) is preferred, but only 20% of patients are eligible. Requirements for safe SCT include NT‐proBNP <5,000 ng/mL, troponin T <0.06 ng/mL, age <70 years, <3 organs involved, and serum creatinine ≤1.7 mg/dL. Nontransplant candidates can be offered melphalan–dexamethasone or cyclophosphamide–bortezomib–dexamethasone. Other combinations of chemotherapy with agents such as cyclophosphamide–thalidomide (or lenalidomide)–dexamethasone, bortezomib–dexamethasone, and melphalan–prednisone–lenalidomide have documented activity.Future Challenges: Late diagnosis remains a major obstacle to initiating effective therapy. Recognizing the presenting syndromes is necessary for improving survival.Am. J. Hematol. 89:1133–1140, 2014. © 2014 Wiley Periodicals, Inc.
Coronary artery disease in primary biliary cirrhosis: A systematic review and meta‐analysis of observational studies
Ungprasert, Patompong , Wijarnpreecha, Karn , Ahuja, Wasin , Spanuchart, Ittikorn , Thongprayoon, Charat , Wijarnpreecha, Karn

Hepatology Research | November 19, 2014 | Volume: 45 | Issue: 11 | Pages: 1055-1061

10.1111/hepr.12452 | PMID 25689394 Get It

AimTo investigate the association between primary biliary cirrhosis (PBC) and risk of coronary artery disease (CAD).MethodsWe conducted a systematic review and meta‐analysis of published observational studies that reported relative risks, odd ratios, hazard ratios or standardized incidence ratios with 95% confidence intervals (CI) comparing CAD risk in patients with PBC versus non‐PBC controls. Pooled risk ratios and 95% confidence intervals were combined using a random‐effect model and generic inverse variance of DerSimonian and Laird methods.ResultFour studies with 3362 patients with PBC were identified and included in our data analysis. The pooled risk ratio of CAD in patients with PBC was 1.57 (95% CI, 1.21–2.06). The statistical heterogeneity was low with an I2 of 38%.ConclusionOur study demonstrated a statistically significant increased risk of CAD among patients with PBC.
Intra- and Inter-Patient Symptom Variability in Fibromyalgia: Results of a 90-Day Assessment
Vincent, Ann , McAllister, Samantha J., Whipple, Mary O. , Whipple, Mary, Toussaint, Loren , Whipple, Mary

Musculoskeletal Care | November 19, 2014 | Volume: 13 | Issue: 2 | Pages: 93-100

10.1002/msc.1090 | PMID 25408116 Get It

Endovascular treatment of distal thoracic aortic transection associated with severe thoracolumbar spinal fracture
Chock, Megan M. , Aho, Johnathon M. , Naik, Nimesh D. , Heller, Stephanie F. , Aho, Johnathon, Naik, Nimesh, Clarke, Michelle, Heller, Stephanie, Clarke, Michelle J. , Oderich, Gustavo S.

Vascular | November 18, 2014 | Volume: 23 | Issue: 5 | Pages: 550-552

10.1177/1708538114560458 | PMID 25406266 Get It

Endovascular repair has become the first line of treatment in most patients with blunt aortic injury. The most common mechanism is deceleration injury affecting the aortic isthmus distal to the origin of the left subclavian artery. Injuries of the distal thoracic aorta are uncommon. We report the case of a 25-year-old male patient who presented with paraplegia and distal thoracic aortic pseudoaneurysm associated with severe thoracolumbar vertebral fracture and displacement after a motocross accident. Endovascular repair was performed using total percutaneous technique and conformable C-TAG thoracic stent-graft (WL Gore, Flagstaff, AZ). Following stent-graft placement and angiographic confirmation of absence of endoleak, thoracolumbar spinal fixation was performed in the same operative procedure. This case illustrates a multispecialty approach to complex aortic and vertebral injury and the high conformability of newer thoracic stent-grafts to adapt to tortuous anatomy.